Vitamin C Binds to SARS Coronavirus-2 Main Protease Essential for Viral Replication
T. N. Malla, S. Pandey, L. Aldama, D. Feliz, M. Noda, I. Poudyal, G. N. Phillips, E. A. Stojkovic, M. Schmidt
Abstract
There is an urgent need for anti-viral agents that treat and/or prevent Covid-19 caused by SARS-Coronavirus (CoV-2) infections. The replication of the SARS CoV-2 is dependent on the activity of two cysteine proteases, a papain-like protease, PL-pro, and the 3C-like protease known as main protease Mpro or 3CLpro. The shortest and the safest path to clinical use is the repurposing of drugs with binding affinity to PLpro or 3CLpro that have an established safety profile in humans. Several studies have reported crystal structures of SARS-CoV-2 main protease in complex with FDA approved drugs such as those used in treatment of hepatitis C. Here, we report the crystal structure of 3CLpro in complex Vitamin C (L-ascorbate) bound to the proteins active site at 2.5 [A]ngstrom resolution. The crystal structure of the Vitamin C 3CLpro complex may aid future studies on the effect of Vitamin C not only on the coronavirus main protease but on related proteases of other infectious viruses.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
J. Osipiuk, Saara‐Anne Azizi, … A. Joachimiak·Nature CommunicationsPeer-reviewed·Feb 2, 2021
- Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures
- Structural basis of main proteases of coronavirus bound to drug candidate PF-07321332
- A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors
W. R. Liu, K. S. Yang, … H. S. Hayatshahi·bioRxiv·Jul 28, 2020
- Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors
P. Moon, L. Boike, … D. K. Nomura·bioRxiv·Mar 5, 2022
- Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro